{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:28:08Z","timestamp":1790483288083,"version":"4.1.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MSD","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hepatitis C virus is one of the leading causes of chronic liver disease and liver-related deaths worldwide. The estimated prevalence of chronic hepatitis C viral infection among the general Belgian population was 0.57% (<jats:italic>n<\/jats:italic>\u2009=\u200964,000) in 2015. Although Belgium has had a \u2018Hepatitis C Plan\u2019 since 2014, elimination efforts are unclear. This study employs the best available data and modelling estimates to define the burden of hepatitis C viral infection among key subgroups in Belgium, identify information gaps and propose potential approaches to screening, linkage to care and treatment, and cure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We examined the peer-reviewed and grey literature since 2012 for data on the prevalence of hepatitis C viral infection in Belgium in key subgroups identified by national experts and in the literature. Ultimately, this research is primarily based on data provided by the key stakeholders themselves due to a lack of reliable data in the literature. Based on this, we modelled the treatment rates required to reach elimination of hepatitis C in several subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eleven potential subgroups were identified. There were no data available for two subgroups: generational cohorts and men who have sex with men. In six subgroups, fewer than 3000 people were reported or estimated to have hepatitis C infection. Migrants and people who inject drugs were the most affected subgroups, and children were the least affected subgroup. Only two subgroups are on target to achieve elimination by 2030: patients living with haemophilia and transplant recipients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Removing Belgian treatment reimbursement restrictions in January 2019 was a big step towards eliminating HCV. In addition, increasing surveillance, including with a national registry, treatment prescription by other health-care providers and availability of treatment in local pharmacies are central to improving the current situation and getting on track to reach the 2030 WHO hepatitis C elimination targets in Belgium.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12879-020-4898-y","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T11:03:33Z","timestamp":1582801413000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Eliminating viral hepatitis C in Belgium: the micro-elimination approach"],"prefix":"10.1186","volume":"20","author":[{"given":"Dana","family":"Busschots","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Toghanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Bielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Salomonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr M.","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greet","family":"Hendrickx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Jadoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Nevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Sokal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brixko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathelijne","family":"Peerlinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Apers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Robaeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-2299","authenticated-orcid":false,"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"4898_CR1","doi-asserted-by":"crossref","unstructured":"Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161\u2013176.","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"4898_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","unstructured":"GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age\u2013sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117\u201371.","journal-title":"Lancet"},{"key":"4898_CR3","volume-title":"Global hepatitis report, 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global hepatitis report, 2017. Geneva: WHO; 2017. http:\/\/apps.who.int\/iris\/bitstream\/10665\/255016\/1\/9789241565455-eng.pdf. Accessed 6 Dec, 2018"},{"key":"4898_CR4","volume-title":"Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries","author":"WHO","year":"2018","unstructured":"WHO. Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries. Geneva: World Health Organization; 2018."},{"key":"4898_CR5","unstructured":"Muyldermans G, Van Gucht S, Van Baelen L. Jaarrapport 2016: hepatitis C virus; Wetenschappelijk Instituut Volksgezondheid - Institution Scientifique de sant\u00e9 Publique (WIV-ISP). https:\/\/nrchm.wiv-isp.be\/nl\/ref_centra_labo\/hepatitis\/Rapporten\/Rapport%20HCV%202016.pdf. Accessed 6 Dec, 2018."},{"key":"4898_CR6","first-page":"277","volume":"77","author":"P Van Damme","year":"2014","unstructured":"Van Damme P, Laleman W, St\u00e4rkel P, et al. Hepatitis C epidemiology in Belgium. Acta Gastroenterol Belg. 2014;77:277\u20139.","journal-title":"Acta Gastroenterol Belg"},{"key":"4898_CR7","first-page":"57926","volume-title":"Veiligheid van de voedselketen en Leefmilieu: Protocolakkoord 'HCV-plan'. Belgisch staatsblad- Moniteur Belge,. In. Brussels","author":"Federale Overheidsdienst Volksgezondheid","year":"2014","unstructured":"Federale Overheidsdienst Volksgezondheid. Veiligheid van de voedselketen en Leefmilieu: Protocolakkoord 'HCV-plan'. Belgisch staatsblad- Moniteur Belge,. In. Brussels; 2014. p. 57926\u201340. [C-2014\/24267]"},{"key":"4898_CR8","unstructured":"Mulkay JP: National Hepatitis Plan Belgium. 2017 Viral hepatitis Prevention Board country meeting Belgium, Brussels. http:\/\/www.vhpb.org\/files\/html\/Meetings_and_publications\/Presentations\/BRUS81.pdf. Accessed 5 Jan, 2018."},{"key":"4898_CR9","unstructured":"De Raedt L. Introduction to the Belgian Health System. 2017 Viral Hepatitis Prevention Board country meeting Belgium. http:\/\/www.vhpb.org\/files\/html\/Meetings_and_publications\/Presentations\/BRUS21.pdf. Accessed 6 Dec, 2018."},{"issue":"4","key":"4898_CR10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jhep.2017.06.033","volume":"67","author":"JV Lazarus","year":"2017","unstructured":"Lazarus JV, Wiktor S, Colombo M, Thursz M, Foundation EIL. Micro-elimination \u2013 a path to global elimination of hepatitis C. J Hepatol. 2017;67(4):665\u20136.","journal-title":"J Hepatol"},{"issue":"3","key":"4898_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/s-0038-1666841","volume":"38","author":"JV Lazarus","year":"2018","unstructured":"Lazarus JV, Safreed-Harmon K, Thursz MR, et al. The micro-elimination approach to eliminating hepatitis C: strategic and operational considerations. Semin Liver Dis. 2018;38(3):181\u201392.","journal-title":"Semin Liver Dis"},{"key":"4898_CR12","unstructured":"Control ECfDPa. Surveillance Atlas of Infectious Diseases. 2018; https:\/\/ecdc.europa.eu\/en\/surveillance-atlas-infectious-diseases, 2018."},{"key":"4898_CR13","unstructured":"Sasse A et al. Epidemiologie van AIDS en HIV Infectie in Belgi\u00eb 2014. Wetenschappelijk Instituut Volksgezondheid (WIV-ISP), https:\/\/epidemio.wiv-isp.be\/ID\/reports\/Jaarrapport_HIV-AIDS_2014.pdf\/. Accessed 1 Jan, 2018."},{"issue":"7","key":"4898_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","volume":"16","author":"L Platt","year":"2016","unstructured":"Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797\u2013808.","journal-title":"Lancet Infect Dis"},{"issue":"suppl 3","key":"4898_CR15","doi-asserted-by":"publisher","first-page":"iii314","DOI":"10.1093\/ndt\/gfv183.31","volume":"30","author":"B Bieber","year":"2015","unstructured":"Bieber B, Goodkin DA, Nwankwo N, et al. Hepatitis C prevalence and clinical outcomes in the Dialysis Outcomes and Practice Patterns study. Nephrol Dial Transplant. 2015;30(suppl 3):iii314.","journal-title":"Nephrol Dial Transplant"},{"key":"4898_CR16","unstructured":"Office of the Commissioner General for Refugees and Stateless persons (CGRS) Belgium: Year report 2016. https:\/\/www.cgvs.be\/nl\/cijfers?field_cijfers_month_year_value%5Bvalue%5D%5Byear%5D=2016. Accessed 12 Dec, 2018."},{"issue":"2","key":"4898_CR17","first-page":"159","volume":"18","author":"G Robaeys","year":"2006","unstructured":"Robaeys G, Van Vlierberghe H, Mathei C, Van Ranst M, Bruckers L, Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Gastroenterol Hepatol. 2006;18(2):159\u201366.","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"4898_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12916-017-0856-y","volume":"15","author":"S Mauss","year":"2017","unstructured":"Mauss S, Pol S, Buti M, et al. Late presentation of chronic viral hepatitis for medical care: a consensus definition. BMC Med. 2017;15(1):92.","journal-title":"BMC Med"},{"issue":"1","key":"4898_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/0778-7367-71-10","volume":"71","author":"K Bollaerts","year":"2013","unstructured":"Bollaerts K, Aerts M, Sasse A. Improved benchmark-multiplier method to estimate the prevalence of ever-injecting drug use in Belgium, 2000-10. Arch Public Health. 2013;71(1):10.","journal-title":"Arch Public Health"},{"key":"4898_CR20","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.drugalcdep.2017.04.003","volume":"177","author":"R Bielen","year":"2017","unstructured":"Bielen R, Moreno C, Van Vlierberghe H, et al. Belgian experience with direct acting antivirals in people who inject drugs. Drug Alcohol Depend. 2017;177:214\u201320.","journal-title":"Drug Alcohol Depend"},{"key":"4898_CR21","volume-title":"The modeled impact of improved Hepatitis C Virus (HCV) treatment strategies on HCV prevalence among people who inject drugs (PWIDs) in Belgium. Abstract presented at","author":"CBS Mathe\u00ef","year":"2015","unstructured":"Mathe\u00ef CBS, Brixko C, Blach S, Mulkay JP, Razavi H, Robaeys G. The modeled impact of improved Hepatitis C Virus (HCV) treatment strategies on HCV prevalence among people who inject drugs (PWIDs) in Belgium. Abstract presented at. San-Francisco: AASLD; 2015."},{"issue":"4","key":"4898_CR22","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.jhep.2018.06.018","volume":"69","author":"J Lazarus","year":"2018","unstructured":"Lazarus J, Peric\u00e0s J, Colombo M, Ninburg M, Wiktor S, Thursz M. Viral hepatitis: \u201cE\u201d is for equitable elimination. J Hepatol. 2018;69(4):762\u20134.","journal-title":"J Hepatol"},{"issue":"5","key":"4898_CR23","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.jhep.2018.06.016","volume":"69","author":"AD Marshall","year":"2018","unstructured":"Marshall AD, Pawlotsky JM, Lazarus JV, Aghemo A, Dore GJ, Grebely J. The removal of DAA restrictions in Europe \u2013 one step closer to eliminating HCV as a major public health threat. J Hepatol. 2018;69(5):1188\u201396.","journal-title":"J Hepatol"},{"issue":"2","key":"4898_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S2468-1253(17)30284-4","volume":"3","author":"AD Marshall","year":"2018","unstructured":"Marshall AD, Cunningham EB, Nielsen S, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018;3(2):125\u201333.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4898_CR25","volume-title":"Hepatitis C: cut-off\u2019s elastography and biological testing for METAVIR F3-F4 and treatment options in BELGIUM: update 01\/06\/2018","author":"Belgian Association for Study of the Liver [website]","year":"2018","unstructured":"Belgian Association for Study of the Liver [website]. In Hepatitis C: cut-off\u2019s elastography and biological testing for METAVIR F3-F4 and treatment options in BELGIUM: update 01\/06\/2018. 2018. Available at: http:\/\/www.basl.be\/hcvguidelinesbelgium."},{"key":"4898_CR26","unstructured":"Antivirale geneesmiddelen tegen hepatitis C: vergoedingsvoorwaarden vanaf 1 januari 2017 - RIZIV. 2018. http:\/\/www.riziv.fgov.be\/nl\/themas\/kost-terugbetaling\/door-ziekenfonds\/geneesmiddel-gezondheidsproduct\/terugbetalen\/specialiteiten\/wijzigingen\/Paginas\/antiretrovirale_hepatitisc_terugbetalingsvoorwaarden_20170101.aspx#.Ww0_40iFNPY. Accessed 29 May, 2018."},{"key":"4898_CR27","unstructured":"Antivirale geneesmiddelen tegen hepatitis C: vergoedingsvoorwaarden vanaf 1 januari 2019 - RIZIV. 2019. https:\/\/www.inami.fgov.be\/nl\/themas\/kost-terugbetaling\/door-ziekenfonds\/geneesmiddel-gezondheidsproduct\/terugbetalen\/specialiteiten\/wijzigingen\/Paginas\/antivirale-hepatitisc-terugbetalingsvoorwaarden_20190101.aspx. Accessed 15 February, 2019."},{"issue":"3","key":"4898_CR28","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jval.2017.01.013","volume":"20","author":"W Crown","year":"2017","unstructured":"Crown W, Buyukkaramikli N, Thokala P, et al. Constrained optimization methods in health services research-an introduction: report 1 of the ISPOR optimization methods emerging good practices task force. Value Health. 2017;20(3):310\u20139.","journal-title":"Value Health"},{"key":"4898_CR29","doi-asserted-by":"publisher","first-page":"e25052","DOI":"10.1002\/jia2.25052","volume":"21","author":"JV Lazarus","year":"2018","unstructured":"Lazarus JV, Stumo SR, Harris M, et al. Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017. J Intern AIDS Soc. 2018;21:e25052.","journal-title":"J Intern AIDS Soc"},{"issue":"5 Suppl 1","key":"4898_CR30","first-page":"S106","volume":"36","author":"EA Roberts","year":"2002","unstructured":"Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology. 2002;36(5 Suppl 1):S106\u201313.","journal-title":"Hepatology."},{"issue":"4","key":"4898_CR31","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.3748\/wjg.v22.i4.1382","volume":"22","author":"PA Tovo","year":"2016","unstructured":"Tovo PA, Calitri C, Scolfaro C, Gabiano C, Garazzino S. Vertically acquired hepatitis C virus infection: correlates of transmission and disease progression. World J Gastroenterol. 2016;22(4):1382\u201392.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"4898_CR32","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2143\/ACB.3315","volume":"68","author":"L Apers","year":"2013","unstructured":"Apers L, Koole O, Bottieau E, et al. Incidence of HCV and sexually transmitted diseases among HIV positive MSM in Antwerp, Belgium, 2001-2011. Acta Clin Belg. 2013;68(6):421\u20136.","journal-title":"Acta Clin Belg"},{"issue":"39","key":"4898_CR33","doi-asserted-by":"crossref","first-page":"19673","DOI":"10.2807\/ese.15.39.19673-en","volume":"15","author":"E Bottieau","year":"2010","unstructured":"Bottieau E, Apers L, Van Esbroeck M, Vandenbruaene M, Florence E. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009. Euro Surveill. 2010;15(39):19673.","journal-title":"Euro Surveill"},{"key":"4898_CR34","unstructured":"Botterman R, Glorieus E, Lefere S, et al. Do or don\u2019t: HCV screening in the Belgian Baby Boom Cohort. In: BWGE2017; 2017; Antwerp. https:\/\/bwge2017.sched.com\/event\/9DfC\/do-or-dont-hcv-screening-in-the-belgian-baby-boom-cohort, accessed 6 Dec, 2018."},{"issue":"4","key":"4898_CR35","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/liv.14016","volume":"39","author":"R Bielen","year":"2018","unstructured":"Bielen R, Kremer C, Koc \u00d6, et al. Screening for hepatitis C at the emergency department: should baby boomers also be screened in Belgium? Liver Int. 2018;39(4):667\u201375.","journal-title":"Liver Int"},{"issue":"4","key":"4898_CR36","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/ndt\/gfh012","volume":"19","author":"M Jadoul","year":"2004","unstructured":"Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19(4):904\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"4898_CR37","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ki.1996.122","volume":"49","author":"L Stuyver","year":"1996","unstructured":"Stuyver L, Claeys H, Wyseur A, et al. Hepatitis C virus in a hemodialysis unit: molecular evidence for nosocomial transmission. Kidney Int. 1996;49(3):889\u201395.","journal-title":"Kidney Int"},{"issue":"Suppl 109","key":"4898_CR38","first-page":"1","volume":"73","author":"D Wheeler","year":"2008","unstructured":"Wheeler D, Winkelmayer WC. The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008;73(Suppl 109):1\u201399.","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"4898_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1159\/000355615","volume":"38","author":"DA Goodkin","year":"2013","unstructured":"Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013;38(5):405\u201312.","journal-title":"Am J Nephrol"},{"issue":"2","key":"4898_CR40","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2215\/CJN.07940716","volume":"12","author":"DA Goodkin","year":"2017","unstructured":"Goodkin DA, Bieber B, Jadoul M, Martin P, Kanda E, Pisoni RL. Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis. Clin J Am Soc Nephrol. 2017;12(2):287\u201397.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"4898_CR41","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.kint.2018.06.011","volume":"94","author":"M Jadoul","year":"2018","unstructured":"Jadoul M, Berenguer MC, Doss W, et al. Executive summary of the 2018 KDIGO hepatitis C in CKD guideline: welcoming advances in evaluation and management. Kidney Int. 2018;94(4):663\u201373.","journal-title":"Kidney Int"},{"key":"4898_CR42","unstructured":"ECDC technical report: Epidemiological assessment of hepatitis B and C among migrants in the EU\/EEA. 2016. https:\/\/ecdc.europa.eu\/en\/publications-data\/epidemiological-assessment-hepatitis-b-and-c-among-migrants-eueea. Accessed 5 Jan, 2018."},{"issue":"2","key":"4898_CR43","first-page":"280","volume":"77","author":"P Starkel","year":"2014","unstructured":"Starkel P, Vandijck D, Laleman W, et al. The disease burden of hepatitis C in Belgium: development of a realistic disease control strategy. Acta Gastroenterol Belg. 2014;77(2):280\u20134.","journal-title":"Acta Gastroenterol Belg"},{"key":"4898_CR44","unstructured":"WHO Collaborating Center for Drug Statistics Methodology. Definition and general considerations of defined daily dose (DDD). https:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/. Accessed 14 Mar, 2018."},{"issue":"1","key":"4898_CR45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","volume":"66","author":"EASL","year":"2017","unstructured":"EASL. Recommendations on treatment of hepatitis C 2016. J Hepatol. 2017;66(1):153\u201394. https:\/\/doi.org\/10.1016\/j.jhep.2016.09.001 Accessed 6 Dec, 2018.","journal-title":"J Hepatol"},{"issue":"2","key":"4898_CR46","first-page":"227","volume":"79","author":"C Mathei","year":"2016","unstructured":"Mathei C, Bourgeois S, Blach S, et al. Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium. Acta Gastroenterol Belg. 2016;79(2):227\u201332.","journal-title":"Acta Gastroenterol Belg"},{"key":"4898_CR47","volume-title":"World prison population list (11th edition). World Prison Brief","author":"R Walmsley","year":"2015","unstructured":"Walmsley R. World prison population list (11th edition). World Prison Brief 2015; http:\/\/www.prisonstudies.org\/sites\/default\/files\/resources\/downloads\/world_prison_population_list_11th_edition_0.pdf. Accessed 7 Dec, 2018."},{"issue":"2","key":"4898_CR48","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"J-M Pawlotsky","year":"2018","unstructured":"Pawlotsky J-M, Negro F, et al. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461\u2013511.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"4898_CR49","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/jvh.12248","volume":"21","author":"H Razavi","year":"2014","unstructured":"Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat. 2014;21(Suppl 1):34\u201359.","journal-title":"J Viral Hepat"},{"issue":"7","key":"4898_CR50","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1136\/archdischild-2017-312708","volume":"102","author":"E Sokal","year":"2017","unstructured":"Sokal E, Nannini P. Hepatitis C virus in children: the global picture. Arch Dis Child. 2017;102(7):672\u20135.","journal-title":"Arch Dis Child"},{"issue":"44","key":"4898_CR51","doi-asserted-by":"publisher","first-page":"7880","DOI":"10.3748\/wjg.v19.i44.7880","volume":"19","author":"MH El-Shabrawi","year":"2013","unstructured":"El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol. 2013;19(44):7880\u20138.","journal-title":"World J Gastroenterol"},{"issue":"38","key":"4898_CR52","doi-asserted-by":"publisher","first-page":"10783","DOI":"10.3748\/wjg.v21.i38.10783","volume":"21","author":"M Pawlowska","year":"2015","unstructured":"Pawlowska M, Domagalski K, Pniewska A, Smok B, Halota W, Tretyn A. What's new in hepatitis C virus infections in children? World J Gastroenterol. 2015;21(38):10783\u20139.","journal-title":"World J Gastroenterol"},{"issue":"16","key":"4898_CR53","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.2143\/TVG.62.16.5002532","volume":"62","author":"P Vanhaesebrouck","year":"2006","unstructured":"Vanhaesebrouck P, Roelens K, De Praeter C, Robberecht E, Goossens L, Leroux-Roels G. Aanpak bij perinatale hepatitis C-virusinfectie. Tijdschrift voor Geneeskunde. 2006;62(16):1124\u20138.","journal-title":"Tijdschrift voor Geneeskunde"},{"issue":"5","key":"4898_CR54","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S2468-1253(17)30045-6","volume":"2","author":"European Union HCV Collaborators","year":"2017","unstructured":"European Union HCV Collaborators. Hepatitis C virus prevalence and level ofintervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(5):325\u201336.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"4898_CR55","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.jhep.2017.08.008","volume":"67","author":"JM Pascasio","year":"2017","unstructured":"Pascasio JM, Vinaixa C, Ferrer MT, et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol. 2017;67(6):1168\u201376.","journal-title":"J Hepatol"},{"issue":"3","key":"4898_CR56","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/hep.28926","volume":"65","author":"J Chhatwal","year":"2017","unstructured":"Chhatwal J, Samur S, Kues B, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017;65(3):777\u201388.","journal-title":"Hepatology."},{"issue":"3","key":"4898_CR57","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","volume":"65","author":"LS Belli","year":"2016","unstructured":"Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65(3):524\u201331.","journal-title":"J Hepatol"},{"issue":"6","key":"4898_CR58","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","volume":"16","author":"M Manns","year":"2016","unstructured":"Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16(6):685\u201397.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"4898_CR59","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"M Charlton","year":"2015","unstructured":"Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649\u201359.","journal-title":"Gastroenterology."},{"issue":"2","key":"4898_CR60","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/10245332.2001.11746564","volume":"6","author":"M Franchini","year":"2001","unstructured":"Franchini M, Tagliaferri A, Rossetti G, et al. The natural history of hepatitis C virus infection in hemophiliacs. Hematology. 2001;6(2):135\u201342.","journal-title":"Hematology."},{"key":"4898_CR61","doi-asserted-by":"crossref","unstructured":"Fransen van de Putte DE, Makris M, Fischer K, et al. long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders. J Hepatol 2014;60(1):39\u201345.","DOI":"10.1016\/j.jhep.2013.08.010"},{"key":"4898_CR62","unstructured":"Irish Haemophilia Society: treatment for hepatitis c; press release 2016. https:\/\/haemophilia.ie\/hiv-hepatitis-c\/hepatitis-c-2\/treatment-for-hepatitis-c\/. Accessed 5 Jan, 2018."},{"issue":"1","key":"4898_CR63","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/ndt\/11.supp4.36","volume":"11","author":"M Jadoul","year":"1996","unstructured":"Jadoul M. Transmission routes of HCV infection in dialysis. Nephrol Dial Transplant. 1996;11(1):36\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"4898_CR64","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","volume":"152","author":"D Goldberg","year":"2017","unstructured":"Goldberg D, Ditah IC, Saeian K, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology. 2017;152(5):1090\u20139 e1091.","journal-title":"Gastroenterology."},{"issue":"6","key":"4898_CR65","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/hep.29097","volume":"65","author":"C Fernandez Carrillo","year":"2017","unstructured":"Fernandez Carrillo C, Lens S, Llop E, et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C registry. Hepatology. 2017;65(6):1810\u201322.","journal-title":"Hepatology"},{"issue":"2","key":"4898_CR66","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jhep.2016.09.004","volume":"66","author":"P Ingiliz","year":"2017","unstructured":"Ingiliz P, Martin TC, Rodger A, et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol. 2017;66(2):282\u20137.","journal-title":"J Hepatol"},{"key":"4898_CR67","unstructured":"Gore C, Lazarus JV, Baptista Leite R, et al. Road to elimination: barriers and best practices in hepatitis C management: overview of the status of HCV care in Europe and Australia. Boston Consulting Group, 2017. http:\/\/image-src.bcg.com\/Images\/BCG-Road-to-Elimination_tcm104-166034.pdf. Accessed 5 Jan, 2018."},{"issue":"5","key":"4898_CR68","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1097\/QAI.0000000000000528","volume":"68","author":"L Apers","year":"2015","unstructured":"Apers L, Vanden Berghe W, De Wit S, et al. Risk factors for HCV acquisition among HIV-positive MSM in Belgium. J Acquir Immune Defic Syndr. 2015;68(5):585\u201393.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"RR-4","key":"4898_CR69","first-page":"1","volume":"61","author":"BD Smith","year":"2012","unstructured":"Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945\u20131965. MMWR Recomm Rep. 2012;61(RR-4):1\u201332.","journal-title":"MMWR Recomm Rep"},{"issue":"4","key":"4898_CR70","doi-asserted-by":"publisher","first-page":"263","DOI":"10.7326\/0003-4819-156-4-201202210-00378","volume":"156","author":"DB Rein","year":"2012","unstructured":"Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156(4):263\u201370.","journal-title":"Ann Intern Med"},{"key":"4898_CR71","first-page":"1","volume-title":"Combating the silent epidemic of viral hepatitis: action plan for the prevention, care, and treatment of viral hepatitis. HHS","author":"US Department of Health and Human Services","year":"2011","unstructured":"US Department of Health and Human Services. Combating the silent epidemic of viral hepatitis: action plan for the prevention, care, and treatment of viral hepatitis. HHS. Washington: HHS; 2011. p. 1\u201376."},{"issue":"2","key":"4898_CR72","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/add.13614","volume":"112","author":"S Trias-Llimos","year":"2017","unstructured":"Trias-Llimos S, Bijlsma MJ, Janssen F. The role of birth cohorts in long-term trends in liver cirrhosis mortality across eight European countries. Addiction. 2017;112(2):250\u20138.","journal-title":"Addiction"},{"issue":"1","key":"4898_CR73","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12879-017-2908-5","volume":"18","author":"AM Falla","year":"2018","unstructured":"Falla AM, Ahmad AA, Duffell E, Noori T, Veldhuijzen IK. Estimating the scale of chronic hepatitis C virus infection in the EU\/EEA: a focus on migrants from anti-HCV endemic countries. BMC Infect Dis. 2018;18(1):42.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"4898_CR74","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jhep.2015.04.026","volume":"63","author":"S Sharma","year":"2015","unstructured":"Sharma S, Carballo M, Feld J, Janssen H. Immigration and viral hepatitis. J Hepatol. 2015;63(2):515\u201322.","journal-title":"J Hepatol"},{"key":"4898_CR75","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.drugpo.2017.05.019","volume":"47","author":"J Grebely","year":"2017","unstructured":"Grebely J, Bruneau J, Lazarus JV, et al. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Int J Drug Policy. 2017;47:51\u201360.","journal-title":"Int J Drug Policy."},{"key":"4898_CR76","volume-title":"Annual epidemiological report 2016 \u2013 hepatitis C","author":"European Centre for Disease Prevention and Control (ECDC)","year":"2016","unstructured":"European Centre for Disease Prevention and Control (ECDC). Annual epidemiological report 2016 \u2013 hepatitis C. Stockholm: ECDC; 2016."},{"issue":"9737","key":"4898_CR77","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0140-6736(10)60742-8","volume":"376","author":"L Degenhardt","year":"2010","unstructured":"Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376(9737):285\u2013301.","journal-title":"Lancet."},{"issue":"1","key":"4898_CR78","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/infdis\/jir196","volume":"204","author":"H Hagan","year":"2011","unstructured":"Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1):74\u201383.","journal-title":"J Infect Dis"},{"issue":"1","key":"4898_CR79","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drugpo.2013.07.001","volume":"25","author":"GJ MacArthur","year":"2014","unstructured":"MacArthur GJ, van Velzen E, Palmateer N, et al. Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25(1):34\u201352.","journal-title":"Int J Drug Policy"},{"issue":"11","key":"4898_CR80","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1111\/j.1360-0443.2011.03515.x","volume":"106","author":"KM Turner","year":"2011","unstructured":"Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978\u201388.","journal-title":"Addiction."},{"issue":"3","key":"4898_CR81","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/add.14012","volume":"113","author":"L Platt","year":"2018","unstructured":"Platt L, Minozzi S, Reed J, et al. Needle syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis. Addiction. 2018;113(3):545\u201363. https:\/\/doi.org\/10.1111\/add.14012 [Epub ahead of print]).","journal-title":"Addiction"},{"issue":"10","key":"4898_CR82","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/aje\/kwn237","volume":"168","author":"H Hagan","year":"2008","unstructured":"Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10):1099\u2013109.","journal-title":"Am J Epidemiol"},{"issue":"7","key":"4898_CR83","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/cid\/ciw869","volume":"64","author":"MD Morris","year":"2017","unstructured":"Morris MD, Shiboski S, Bruneau J, et al. Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: the InC3 collaboration. Clin Infect Dis. 2017;64(7):860\u20139.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"4898_CR84","doi-asserted-by":"publisher","first-page":"e103345","DOI":"10.1371\/journal.pone.0103345","volume":"9","author":"L Wiessing","year":"2014","unstructured":"Wiessing L, Ferri M, Grady B, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014;9(7):e103345.","journal-title":"PLoS One"},{"issue":"5","key":"4898_CR85","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.drugpo.2007.02.005","volume":"18","author":"E Roy","year":"2007","unstructured":"Roy E, Nonn E, Haley N, Cox J. Hepatitis C meanings and preventive strategies among street-involved young injection drug users in Montr\u00e9al. Int J Drug Policy. 2007;18(5):397\u2013405.","journal-title":"Int J Drug Policy"},{"issue":"1 Suppl","key":"4898_CR86","first-page":"411A","volume":"64","author":"R Bielen","year":"2016","unstructured":"Bielen R, Verrando R, Penders J, Oris E, Nevens F, Robaeys G. Case management to improve uptake for screening and therapy of hepatitis C viral infection in people who inject drugs. Hepatology. 2016;64(1 Suppl):411A\u20132A.","journal-title":"Hepatology."},{"issue":"10049","key":"4898_CR87","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S0140-6736(16)30466-4","volume":"388","author":"K Dolan","year":"2016","unstructured":"Dolan K, Wirtz AL, Moazen B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089\u2013102.","journal-title":"Lancet."},{"issue":"10050","key":"4898_CR88","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0140-6736(16)30856-X","volume":"388","author":"FL Altice","year":"2016","unstructured":"Altice FL, Azbel L, Stone J, et al. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016;388(10050):1228\u201348.","journal-title":"Lancet."},{"issue":"8","key":"4898_CR89","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1086\/533454","volume":"197","author":"D Richardson","year":"2008","unstructured":"Richardson D, Fisher M, Sabin CA. Sexual transmission of hepatitis C in MSM may not be confined to those with HIV infection. J Infect Dis. 2008;197(8):1213\u20134 author reply 1214\u20131215.","journal-title":"J Infect Dis"},{"issue":"2","key":"4898_CR90","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/OLQ.0b013e3181ec9de5","volume":"38","author":"TJ van de Laar","year":"2011","unstructured":"van de Laar TJ, Paxton WA, Zorgdrager F, Cornelissen M, de Vries HJ. Sexual transmission of hepatitis C virus in human immunodeficiency virus-negative men who have sex with men: a series of case reports. Sex Transm Dis. 2011;38(2):102\u20134.","journal-title":"Sex Transm Dis"},{"issue":"11","key":"4898_CR91","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/cid\/civ129","volume":"60","author":"JE Volk","year":"2015","unstructured":"Volk JE, Marcus JL, Phengrasamy T, Hare CB. Incident hepatitis C virus infections among users of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;60(11):1728\u20139.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"4898_CR92","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1097\/QAD.0000000000001522","volume":"31","author":"E Hoornenborg","year":"2017","unstructured":"Hoornenborg E, Achterbergh RCA. Schim Van Der Loeff MF, et al. men who have sex with men starting pre-exposure prophylaxis (PrEP) are at risk of HCV infection: evidence from the Amsterdam PrEP study. AIDS. 2017;31(11):1603\u201310.","journal-title":"AIDS."},{"issue":"3","key":"4898_CR93","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/jvh.12809","volume":"25","author":"V Saludes","year":"2018","unstructured":"Saludes V, Folch C, Morales-Carmona A, et al. Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: analysis of key populations in Barcelona. Spain J Viral Hepat. 2018;25(3):236\u201344.","journal-title":"Spain J Viral Hepat"},{"key":"4898_CR94","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jhep.2017.10.010","volume":"68","author":"H Fraser","year":"2018","unstructured":"Fraser H, Martin NK, Brummer-Korvenkontio H, et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol. 2018;68:402\u201311.","journal-title":"J Hepatol"},{"key":"4898_CR95","volume-title":"Hepatitis C virus reinfection and injecting risk behavior following elbasvir\/grazoprevir treatment in participants on opiate agonist therapy: C-EDGE CO-STAR Part B","author":"G Dore","year":"2017","unstructured":"Dore G, Grebely J, Altice F, et al. Hepatitis C virus reinfection and injecting risk behavior following elbasvir\/grazoprevir treatment in participants on opiate agonist therapy: C-EDGE CO-STAR Part B. Washington, D.C: AASLD Annual Meeting; 2017."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-4898-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-4898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T18:57:29Z","timestamp":1665946649000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-4898-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4898"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-4898-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"3 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\u201cNot applicable\u201d.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"\u201cNot applicable\u201d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.B. has received travel grants from AbbVie. S.T. and S.S are employees of MSD. R.B. has received travel grants from AbbVie, Gilead Sciences and MSD to attend scientific congresses and research grants from Gilead and MSD. \u00d6.K. has received a travel grant and research grants from Gilead. G.H. declares to be member of the VHPB secretariat for which the University of Antwerp obtains unrestricted grants from different vaccine and pharma manufacturers (AbbVie, Gilead, GlaxoSmithKline Biologicals, Merck, MSD and Sanofi Pasteur). M.J. has received speaker\/ consultancy fees from MSD and AbbVie, and a research grant from MSD. F.N. has received research grants, consultancy agreements and travel grants from AbbVie, Astellas, BMS, CAF, Durect, Ferring, Gilead Sciences, Gore, Janssen-Cilag, Intercept, Ipsen, MSD, Novartis, Ono Pharma, Promethera Biosciences, and UCB. E.S. is an advisor for AbbVie, and investigator for Gilead, Roche. He is the founder and CMO of Promethera Biosciences. B.C. has received travel grants from Abbvie, Gilead and MSD to attend scientific meetings. K.P. declares no conflict of interest. L.A. declares no conflict of interest. G.R. has received research grants from AbbVie, Janssen Pharmaceuticals, MSD, and has acted as a consultant\/advisor for AbbVie, BMS, Gilead Sciences and MSD. J.V.L. has received speaker fees and research grants from AbbVie, Gilead Sciences and MSD. The funders provided the mathematical model used for calculations. All data were provided by the other co-others.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}